Webinar
Research in Motion with ioSkeletal Myocytes™
Introducing human iPSC-derived muscle cells for research and drug discovery.
Introducing human iPSC-derived muscle cells for research and drug discovery.
Dr Will Bernard, Senior Scientist at bit.bio, and Dr Luke Flatt, Senior Scientist at Charles River Laboratories discuss how bit.bio’s iPSC-derived ioSkeletal Myocytes can facilitate high-throughput screening (HTS) workflows and accelerate research into muscle and metabolic disease.
This webinar discusses how bit.bio’s iPSC-derived ioSkeletal Myocytes can facilitate HTS workflows and accelerate research into muscle and metabolic disease.
Learning outcomes:
- How highly-defined and characterised muscle cells can provide physiological relevance earlier in your research and drug development pipeline.
- The potential of ioSkeletal Myocytes as a relevant translational model for research of muscle, neuromuscular and associated metabolic disorders.
- How human induced skeletal myocytes have been generated by opti-ox™ cellular reprogramming to offer consistency at scale, easy culture and rapid maturity.
Dr Luke Flatt | Senior Scientist | Charles River Laboratories
Dr Will Bernard | Senior Scientist | bit.bio
2020
Watch webinar